Investigators in the ADVANCE Study, an international study involving 11,140 high-risk patients with type 2 diabetes, announced that their study provides no evidence of an increased risk of death among those patients receiving intensive treatment to lower blood glucose (sugar). These findings contrast with those reported last week by the U.S. National Heart Lung and Blood Institute suggesting that intensive glucose lowering treatment levels had increased the death rate compared to standard glucose lowering in patients with type 2 diabetes recruited to the ACCORD trial. The ADVANCE interim results were based on more than twice as much data and similar levels of glucose control as in ACCORD. The ADVANCE trial was five years in duration and is currently ending. More definitive and final outcome results from ADVANCE should be available later in the spring.
Read More
No comments:
Post a Comment